Dayvigo
Breakthrough Alzheimer’s Therapies Drive Early Detection Rates While Exposing Deep Treatment Disparities
Analysis from Komodo Health and Medscape Education shows cognitive screening up 10% and biomarker testing up 23%, yet significant disparities persist in detection for women and treatment access for Black...
Lilly launches global Alzheimer’s campaign with Julianne Moore
The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health
David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare
Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site
MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease
Approximately one in every 70,000 people are affected by the tumour-causing genetic disease
Merck and Daiichi Sankyo to jointly develop T-cell engager in deal worth over $170m
The partners will evaluate MK-6070 as part of a combination treatment for small cell lung cancer
Merck and Astellas/Pfizer’s bladder cancer combination receives positive CHMP opinion
More than 165,000 new cases of bladder cancer are diagnosed in the EU every year
Merck’s Keytruda combination recommended by NICE for advanced gastric cancer
More than 6,500 new cases of gastric cancer are diagnosed in the UK every year
Merck’s investigational RSV monoclonal antibody clesrovimab shown to protect infants
The respiratory virus accounts for about 30,000 hospitalisations in children under five every year in the UK
ICR study reveals Lynparza could treat more advanced prostate cancer patients
Up to 30% of men living with the advanced disease have tumours that contain defects in repairing DNA
Merck’s pulmonary arterial hypertension therapy receives CHMP recommendation
Approximately 30,000 people in the EU are currently living with the rare blood disorder
Merck’s adult-specific pneumococcal vaccine Capvaxive granted FDA approval
The vaccine is designed to protect against the strains responsible for the majority of adult invasive pneumococcal disease
Merck to expand ophthalmology pipeline with acquisition of EyeBio in deal worth up to $3bn
Merck will gain access to EyeBio’s Restoret to prevent and treat retinal vascular leakage-associated vision loss